Sunday 25 March 2012

Subcutaneous Injection-Comparable Efficacy-Administration-Breast Cancer-Herceptin

Roche's Herceptin given by subcutaneous injection offers greater convenience to patients and reduces overall healthcare costs compared to standard IV infusion

Subcutaneous administration of Herceptin is less invasive and takes approximately 5 minutes instead of 30-90 minutes with currently approved IV administration. Roche today announced results from the Phase III HannaH study in women with HER2-positive early breast cancer (eBC) showing for the first time that a new way of giving Herceptin (trastuzumab) by subcutaneous (SC) injection leads to comparable efficacy (based on pathological complete response (pCR); complete eradication of the tumour cells in the breast) to the current way of giving the medicine by intravenous (IV) route. (Source: Roche Investor Update) read more..

No comments:

Post a Comment